Price
$25.3
Increased by +0.24%
Dollar Volume (20D)
5.72 M
ADR%
8.35
Earnings Report Date (estimate)
May 13, 24
Shares Float
10.1 M
Shares Outstanding
27.86 M
Shares Short
993.09 K
Market Cap.
682.64 M
Beta
1.23
Price / Earnings
N/A
20D Range
24.27 32.41
50D Range
16.74 32.41
200D Range
9.41 32.41
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Mar 27, 24 -0.74
Decreased by -21.31%
-0.71
Decreased by -4.23%
Nov 13, 23 -0.71
Decreased by -26.79%
-0.69
Decreased by -2.9%
Aug 14, 23 -0.76
Decreased by -55.1%
-0.7
Decreased by -8.57%
May 15, 23 -0.67
Decreased by -48.89%
-0.6
Decreased by -11.67%
Mar 29, 23 -0.61
Decreased by -74.29%
-0.62
Increased by +1.61%
Nov 14, 22 -0.56
Decreased by -115.38%
-0.5
Decreased by -12%
Aug 15, 22 -0.49
Increased by +97.94%
-0.45
Decreased by -8.89%
May 16, 22 -0.45
Increased by +96.48%
-0.28
Decreased by -60.71%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 23 0
Decreased by N/A%
-20.41 M
Decreased by -35.89%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0
Decreased by N/A%
-19.56 M
Decreased by -50.21%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-19.02 M
Decreased by -61.68%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-15.4 M
Decreased by -42.59%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-15.02 M
Decreased by -82.68%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-13.02 M
Decreased by -110.61%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-11.77 M
Decreased by -103.76%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-10.8 M
Decreased by -288.39%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.